Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis
ConclusionOsimertinib treatment yields approximately 10 months PFS in prior EGFR-TKI-treated and 20 months in treatment-na ïve NSCLC patients. Partial response rate is also higher in treatment-naïve patients. However, objective response rate (ORR) and disease control rate (DCR) did not differ between groups of patients.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Lung Cancer | Non-Small Cell Lung Cancer | Study